ChromaDex (NASDAQ:CDXC) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of ChromaDex (NASDAQ:CDXC) in a research report report published on Monday. The firm issued a buy rating on the stock.

A number of other equities analysts have also recently issued reports on CDXC. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of ChromaDex in a report on Monday, March 17th. LADENBURG THALM/SH SH raised their price objective on shares of ChromaDex from $6.80 to $8.10 and gave the company a “buy” rating in a research note on Wednesday, March 5th.

ChromaDex Stock Performance

ChromaDex has a 52 week low of $2.31 and a 52 week high of $9.18. The business’s fifty day moving average price is $6.16 and its 200 day moving average price is $5.44. The firm has a market cap of $611.50 million, a P/E ratio of 787.29 and a beta of 2.21.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of CDXC. Geode Capital Management LLC boosted its holdings in ChromaDex by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,154,778 shares of the company’s stock worth $6,128,000 after acquiring an additional 5,186 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in ChromaDex by 1,785.9% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,011,290 shares of the company’s stock worth $5,365,000 after purchasing an additional 957,665 shares during the last quarter. Renaissance Technologies LLC grew its position in ChromaDex by 68.0% in the 4th quarter. Renaissance Technologies LLC now owns 712,788 shares of the company’s stock worth $3,781,000 after purchasing an additional 288,588 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in ChromaDex by 288.1% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 662,956 shares of the company’s stock valued at $3,517,000 after buying an additional 492,148 shares during the last quarter. Finally, State Street Corp increased its stake in ChromaDex by 11.3% in the 3rd quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after buying an additional 62,692 shares during the last quarter. Hedge funds and other institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.